Biomarin Pharmaceutical (BMRN) Receivables - Net: 2009-2025
Historic Receivables - Net for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $790.3 million.
- Biomarin Pharmaceutical's Receivables - Net rose 1.64% to $790.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $790.3 million, marking a year-over-year increase of 1.64%. This contributed to the annual value of $660.5 million for FY2024, which is 4.23% up from last year.
- Biomarin Pharmaceutical's Receivables - Net amounted to $790.3 million in Q3 2025, which was down 7.66% from $855.9 million recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year Receivables - Net high stood at $855.9 million for Q2 2025, and its period low was $373.4 million during Q4 2021.
- Its 3-year average for Receivables - Net is $687.8 million, with a median of $660.5 million in 2024.
- In the last 5 years, Biomarin Pharmaceutical's Receivables - Net dropped by 16.72% in 2021 and then surged by 39.00% in 2023.
- Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Receivables - Net stood at $373.4 million in 2021, then climbed by 23.55% to $461.3 million in 2022, then soared by 37.37% to $633.7 million in 2023, then grew by 4.23% to $660.5 million in 2024, then rose by 1.64% to $790.3 million in 2025.
- Its Receivables - Net was $790.3 million in Q3 2025, compared to $855.9 million in Q2 2025 and $739.2 million in Q1 2025.